Family Capital Management Inc. Buys 5,122 Shares of Merck & Co., Inc. $MRK

Family Capital Management Inc. increased its stake in Merck & Co., Inc. (NYSE:MRK) by 135.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 8,901 shares of the company’s stock after purchasing an additional 5,122 shares during the period. Family Capital Management Inc.’s holdings in Merck & Co., Inc. were worth $705,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. Barnes Dennig Private Wealth Management LLC bought a new position in Merck & Co., Inc. during the first quarter valued at approximately $27,000. Legend Financial Advisors Inc. bought a new position in Merck & Co., Inc. during the second quarter valued at approximately $25,000. CBIZ Investment Advisory Services LLC grew its position in Merck & Co., Inc. by 141.7% during the first quarter. CBIZ Investment Advisory Services LLC now owns 377 shares of the company’s stock valued at $34,000 after acquiring an additional 221 shares during the last quarter. MorganRosel Wealth Management LLC bought a new position in Merck & Co., Inc. during the first quarter valued at approximately $36,000. Finally, Fiduciary Wealth Partners LLC bought a new position in Merck & Co., Inc. during the first quarter valued at approximately $48,000. 76.07% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. Morgan Stanley reduced their price target on shares of Merck & Co., Inc. from $99.00 to $98.00 and set an “equal weight” rating on the stock in a research report on Thursday, July 10th. Wells Fargo & Company reduced their price target on shares of Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 30th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Merck & Co., Inc. in a research report on Wednesday, October 8th. Citigroup started coverage on shares of Merck & Co., Inc. in a report on Monday, October 13th. They issued a “neutral” rating and a $95.00 target price on the stock. Finally, Berenberg Bank cut shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating and cut their target price for the stock from $100.00 to $90.00 in a report on Wednesday, September 17th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, thirteen have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $104.33.

Merck & Co., Inc. Stock Performance

Shares of MRK stock opened at $87.61 on Wednesday. The stock has a fifty day moving average of $84.18 and a 200 day moving average of $81.39. Merck & Co., Inc. has a 52 week low of $73.31 and a 52 week high of $107.36. The firm has a market capitalization of $218.83 billion, a price-to-earnings ratio of 13.50, a PEG ratio of 0.95 and a beta of 0.37. The company has a quick ratio of 1.17, a current ratio of 1.42 and a debt-to-equity ratio of 0.69.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Tuesday, July 29th. The company reported $2.13 EPS for the quarter, topping analysts’ consensus estimates of $2.03 by $0.10. Merck & Co., Inc. had a return on equity of 41.05% and a net margin of 25.79%.The company had revenue of $15.81 billion during the quarter, compared to analyst estimates of $15.92 billion. Merck & Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS. As a group, research analysts expect that Merck & Co., Inc. will post 9.01 earnings per share for the current year.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.